{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:39:25Z","timestamp":1794742765472,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NIH 5 P30 CA06516"],"award-info":[{"award-number":["NIH 5 P30 CA06516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA206963"],"award-info":[{"award-number":["CA206963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA066996"],"award-info":[{"award-number":["CA066996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA259273"],"award-info":[{"award-number":["CA259273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","award":["Chromatin Collaborative award"],"award-info":[{"award-number":["Chromatin Collaborative award"]}],"id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["511811315"],"award-info":[{"award-number":["511811315"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PE 3217\/4-1, PN: 517204983"],"award-info":[{"award-number":["PE 3217\/4-1, PN: 517204983"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2021-EKEA.111"],"award-info":[{"award-number":["2021-EKEA.111"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Menin inhibitors have entered clinical trials for\n                    <jats:italic>histone lysine methyltransferase 2\u2009A (KMT2A)<\/jats:italic>\n                    -rearranged and\n                    <jats:italic>nucleophosmin 1 (NPM1)<\/jats:italic>\n                    -mutant acute leukemias and are demonstrating promising activity. CRISPR base editor screening previously predicted several\n                    <jats:italic>MEN1<\/jats:italic>\n                    (menin) mutations that have arisen in patients receiving SNDX-5613 and confer resistance. The extent to which\n                    <jats:italic>MEN1<\/jats:italic>\n                    mutations will impact each menin inhibitor is mostly unknown. Here we show that CRISPR base editor screens can be leveraged to profile the\n                    <jats:italic>MEN1<\/jats:italic>\n                    mutations that may impact five different menin inhibitors in clinical trials. We identify shared (M327I\/V\/T, G331D) and inhibitor-specific (C334R, E368K\/V, V372A) resistance mutations. Co-crystal structures of menin bound to each menin inhibitor suggest resistance mechanisms related to how each inhibitor engages the KMT2A binding pocket of menin. Orthogonal in vitro and in vivo\n                    <jats:italic>MEN1<\/jats:italic>\n                    mutation generation under therapeutic pressure suggest the\n                    <jats:italic>MEN1<\/jats:italic>\n                    mutations identified with CRISPR base editor screening are likely to arise and impact all menin inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-72685-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:55:47Z","timestamp":1778291747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials"],"prefix":"10.1038","volume":"17","author":[{"given":"Wallace","family":"Bourgeois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-9104","authenticated-orcid":false,"given":"Daniela V.","family":"Wenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-3321","authenticated-orcid":false,"given":"Florian","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D.","family":"Regalado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-4427","authenticated-orcid":false,"given":"Jan C.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Sommerschield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-4291","authenticated-orcid":false,"given":"Charlie","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Bijpuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6007-7591","authenticated-orcid":false,"given":"Jordan F.","family":"Safer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-4374","authenticated-orcid":false,"given":"Sumaiya","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2636-0952","authenticated-orcid":false,"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-6306","authenticated-orcid":false,"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"McGeehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-4292","authenticated-orcid":false,"given":"Jevon A.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-4728","authenticated-orcid":false,"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"72685_CR1","doi-asserted-by":"crossref","unstructured":"Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207\u2013218 (2005).","DOI":"10.1016\/j.cell.2005.09.025"},{"key":"72685_CR2","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW Kuhn","year":"2016","unstructured":"Kuhn, M. W. et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 6, 1166\u20131181 (2016).","journal-title":"Cancer Discov."},{"key":"72685_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277\u2013284 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"72685_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov, A. V. et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell 36, 660\u2013673 e611 (2019).","journal-title":"Cancer Cell"},{"key":"72685_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski, S. et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J. Clin. Invest 130, 981\u2013997 (2020).","journal-title":"J. Clin. Invest"},{"key":"72685_CR6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon, M. C. et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 144, 1206\u20131220 (2024).","journal-title":"Blood"},{"key":"72685_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann, H. J. et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586\u2013590 (2020).","journal-title":"Science"},{"key":"72685_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2643-3230.BCD-24-0212","volume":"6","author":"GC Issa","year":"2025","unstructured":"Issa, G. C., Cai, S. F., Bataller, A., Kantarjian, H. M. & Stein, E. M. Combination strategies with menin inhibitors for acute leukemia. Blood Cancer Discov. 6, 547\u2013560 (2025).","journal-title":"Blood Cancer Discov."},{"key":"72685_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920\u2013924 (2023).","journal-title":"Nature"},{"key":"72685_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa, G. C. et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75\u201384 (2025).","journal-title":"J. Clin. Oncol."},{"key":"72685_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood.2025028357","volume":"146","author":"ML Arellano","year":"2025","unstructured":"Arellano, M. L. et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood 146, 1065\u20131077 (2025).","journal-title":"Blood"},{"key":"72685_CR12","unstructured":"Administration, U. S. F. a. D. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation (2024)."},{"key":"72685_CR13","unstructured":"Administration, U. S. F. a. D. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation (2025)."},{"key":"72685_CR14","unstructured":"Administration, U. S. F. a. D. FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation (2025)."},{"key":"72685_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913\u2013919 (2023).","journal-title":"Nature"},{"key":"72685_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang, E. S. et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 25, 1310\u20131324 (2024).","journal-title":"Lancet Oncol."},{"key":"72685_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28884-7","volume":"13","author":"AK Sangree","year":"2022","unstructured":"Sangree, A. K. et al. Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2. Nat. Commun. 13, 1318 (2022).","journal-title":"Nat. Commun."},{"key":"72685_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02877-y","volume":"23","author":"M Numata","year":"2023","unstructured":"Numata, M. et al. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int 23, 36 (2023).","journal-title":"Cancer Cell Int"},{"key":"72685_CR19","unstructured":"Kamioka, S. et al. Optically active azabicyclo ring derivative. Patent: US20200157114A1. (2020)."},{"key":"72685_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aba8853","volume":"368","author":"RT Walton","year":"2020","unstructured":"Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science 368, 290\u2013296 (2020).","journal-title":"Science"},{"key":"72685_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","volume":"41","author":"ME Neugebauer","year":"2023","unstructured":"Neugebauer, M. E. et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat. Biotechnol. 41, 673\u2013685 (2023).","journal-title":"Nat. Biotechnol."},{"key":"72685_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41592-024-02409-0","volume":"21","author":"S Kwon","year":"2024","unstructured":"Kwon, S. et al. Genomics 2 Proteins portal: a resource and discovery tool for linking genetic screening outputs to protein sequences and structures. Nat. Methods 21, 1947\u20131957 (2024).","journal-title":"Nat. Methods"},{"key":"72685_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature10806","volume":"482","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542\u2013546 (2012).","journal-title":"Nature"},{"key":"72685_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2023021359","volume":"143","author":"JM Barajas","year":"2024","unstructured":"Barajas, J. M. et al. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood 143, 619\u2013630 (2024).","journal-title":"Blood"},{"key":"72685_CR25","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1056\/NEJMc2404110","volume":"390","author":"IS Tiong","year":"2024","unstructured":"Tiong, I. S., Ritchie, D. S. & Blombery, P. Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML. N. Engl. J. Med 390, 2323\u20132325 (2024).","journal-title":"N. Engl. J. Med"},{"key":"72685_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107777","volume":"300","author":"J Ray","year":"2024","unstructured":"Ray, J., Clegg, B., Grembecka, J. & Cierpicki, T. Drug-resistant menin variants retain high binding affinity and interactions with MLL1. J. Biol. Chem. 300, 107777 (2024).","journal-title":"J. Biol. Chem."},{"key":"72685_CR27","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood.2023023644","volume":"144","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood 144, 2018\u20132032 (2024).","journal-title":"Blood"},{"key":"72685_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","volume":"13","author":"YM Soto-Feliciano","year":"2023","unstructured":"Soto-Feliciano, Y. M. et al. A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition. Cancer Discov. 13, 146\u2013169 (2023).","journal-title":"Cancer Discov."},{"key":"72685_CR29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1158\/2159-8290.CD-24-1517","volume":"15","author":"SJV Gordon","year":"2025","unstructured":"Gordon, S. J. V. et al. Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to menin inhibitors in MLL leukemia. Cancer Discov. 15, 2117\u20132138 (2025).","journal-title":"Cancer Discov."},{"key":"72685_CR30","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1021\/acschembio.5c00265","volume":"20","author":"JD Hurley","year":"2025","unstructured":"Hurley, J. D. et al. Decoding protein-peptide interactions using a large, target-agnostic yeast surface display library. ACS Chem. Biol. 20, 2120\u20132133 (2025).","journal-title":"ACS Chem. Biol."},{"key":"72685_CR31","doi-asserted-by":"crossref","unstructured":"Nelakurti, D. D., Pappula, A. L., Rajasekaran, S., Miles, W. O. & Petreaca, R. C. Comprehensive analysis of MEN1 mutations and their role in cancer. Cancers (Basel) 12, 2616 (2020).","DOI":"10.3390\/cancers12092616"},{"key":"72685_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend, E. C. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574\u2013586 (2016).","journal-title":"Cancer Cell"},{"key":"72685_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72685-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72685-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72685-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:03:59Z","timestamp":1784181839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72685-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72685"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72685-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.P. received travel support from Syndax Pharmaceuticals and CHARM Therapeutics. E.S.F. is an advisor and equity holder of Civetta Therapeutics, Proximity Therapeutics, Ajax Therapeutics, Neomorph Inc (also board of directors), Avilar Therapeutics, Stelexis Biosciences, Anvia Therapeutics (also board of directors) and Photys Therapeutics, equity holder in Lighthorse therapeutics and a consultant to Astellas, Sanofi, Novartis, Deerfield, and EcoR1 capital. The Fischer laboratory receives or has received research funding from Novartis, Deerfield, Ajax, Interline, and Astellas. J.A.C. reports consultant and advisory role for Sumitomo Dainippon Pharmaceuticals. S.A.A. has been a consultant and\/or shareholder for Neomorph, C4 Therapeutics, Accent Therapeutics, Hyku Therapeutics, Stelexis BioSciences, and the Novartis Cancer Program. S.A.A. has received research support from Janssen and Syndax. S.A.A. is an inventor on a patent related to Menin inhibition WO\/2017\/132398A1. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6265"}}